Research & Development

This is europe

AstraZeneca to present further research into long-term prevention of cardiovascular events for patients with a history of heart attack at ESC Congress 2015

24th October 2015

Over 20 scientific abstracts from AstraZeneca’s cardiovascular and metabolic disease portfolio will be presented at this year’s European Society of...

US FDA approves expanded indication for BRILINTA to include long-term use in patients with a history of heart attack

by Yuvraj_pawp

24th October 2015

AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved BRILINTA® (ticagrelor) tablets at a new 60mg...

AstraZeneca enters license agreement with Daiichi Sankyo for development and commercialisation of FluMist in Japan

by Yuvraj_pawp

24th October 2015

AstraZeneca today announced that its global biologics research and development arm, MedImmune, has entered an agreement granting Daiichi Sankyo Company,...

Immuno-oncology: an update on progress at the European Cancer Congress

by Yuvraj_pawp

24th October 2015

Within the rapidly evolving world of cancer treatment and the excitement surrounding immuno-oncology, it is more important than ever to...

AstraZeneca presents advances in oncology research at ECC 2015 with data on AZD9291, durvalumab and LYNPARZA™ (olaparib)

by Yuvraj_pawp

24th October 2015

AstraZeneca, along with MedImmune, the company’s global biologics research and development arm, will illustrate the strength and depth of research...

New England Journal of Medicine publishes results of head-to-head studies of brodalumab versus ustekinumab in psoriasis

by Yuvraj_pawp

24th October 2015

The New England Journal of Medicine (NEJM) has published positive results from two pivotal, multi-centre, Phase III studies –AMAGINE-2 and...

AstraZeneca and Lilly expand immuno-oncology research collaboration with new combinations

by Yuvraj_pawp

24th October 2015

AstraZeneca and Eli Lilly and Company (Lilly) today announced an extension to their existing immuno-oncology collaboration exploring novel combination therapies...

Lilly To Discontinue Development Of Evacetrapib For High-Risk Atherosclerotic Cardiovascular Disease

by Yuvraj_pawp

24th October 2015

Eli Lilly and Company (NYSE: LLY) and the ACCELERATE study's academic leadership have accepted the recommendation of the independent data...

Allergan and Humana Announce Research Partnership to Improve Health Outcomes

by Yuvraj_pawp

5th October 2015

Allergan plc (NYSE: AGN), a leading global specialty pharmaceutical company, today announced a multi-year research collaboration with Humana Inc. (NYSE:...